-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] For a long time, China's high-end medical imaging equipment market has been monopolized by foreign companies, and imported products account for more than 90% of the market
.
In recent years, the aggravation of aging has led to an increase in the demand for medical equipment.
Coupled with the support of technological innovation and favorable policies, China's imaging equipment has gradually broken technical barriers in the low-end field, and has continuously broken through into the blue ocean of the market
.
The industry believes that the domestic medical imaging equipment market space is huge.
In 2020, the scale of China's medical imaging market will be about 600 billion to 800 billion yuan.
In the future, there is still room for domestic alternatives to be tapped
.
In the face of the considerable market blue ocean, a number of enterprises including Mindray Medical, Neusoft Medical, and Wandong Medical have been actively deployed
.
Recently, news of United Imaging Medical's first launch meeting came.
In the next step, United Imaging Medical will submit for registration and is expected to be listed in 2022
.
According to the data, United Imaging Medical was established in March 2011.
It is an enterprise dedicated to providing high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions to global customers
.
The company is headquartered in Shanghai, and has established regional headquarters and R&D centers in the United States, Malaysia, the United Arab Emirates, Poland and other places, and has deployed production capacity in Shanghai, Changzhou, Wuhan, and Houston in the United States, and has established a global R&D, production and service network
.
Financial data shows that the company has been in a state of loss before the epidemic in 2020.
In 2020, medical institutions have increased demand for CT and mobile DR products, driving the company's related product revenue growth
.
From 2019 to 2021, United Imaging Medical achieved revenue of 2.
979 billion yuan, 5.
761 billion yuan and 7.
254 billion yuan respectively, the compound growth rate of revenue was 56.
03%, and the net profit attributable to the parent in the same period was -73.
5198 million yuan, 903 million yuan and 1.
417 billion yuan respectively.
yuan, showing a rapid growth trend
.
However, the proportion of R&D has shown a downward trend year by year
.
From 2019 to 2021, United Imaging Medical's R&D investment was 690 million yuan, 850 million yuan and 1.
048 billion yuan respectively, accounting for 23.
17%, 14.
76% and 14.
45% of its operating income, respectively
.
It is reported that although the proportion of the company's research and development has decreased year by year, it is still at a relatively high level among domestic enterprises in the industry
.
With high R&D investment, United Imaging Medical has a wealth of products.
By the end of 2021, United Imaging Medical has cumulatively launched magnetic resonance imaging systems (MR), X-ray computed tomography (CT), and X-ray imaging systems (XR) to the market.
, molecular imaging system (PET/CT, PET/MR), medical linear accelerator system (RT) and more than 80 products including life science instruments, etc.
, have a certain dominant position in the fields of computer equipment and magnetic resonance imaging
.
United Imaging Medical said that if the company’s future R&D investment is insufficient, or it is limited by uncertain factors such as R&D personnel and R&D conditions, it may lead to the failure to develop new products as planned, the industrialization of research projects, or the development of new products.
There is no competitive advantage in technology, performance, cost, etc.
, which in turn affects its competitive position and market share in the industry
.
It is worth mentioning that United Imaging Medical is favored by capital, and has completed 5 rounds of financing before the IPO.
The investors include CICC, CITIC Securities, CDB Securities and other securities institutions
.
Among them, in September 2017, it received 3.
333 billion yuan in Series A financing, setting a new record for a single private equity financing in China's medical imaging equipment industry, and its valuation has also risen
.
After the exercise of the over-allotment option, United Imaging Medical plans to issue 115 million shares, raise no less than 12.
48 billion yuan, and issue a valuation of more than 100 billion yuan
.
According to the industry, if United Imaging Medical is successfully listed, it may become the second company with a market value of 100 billion in the industry after Mindray Medical.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In recent years, the aggravation of aging has led to an increase in the demand for medical equipment.
Coupled with the support of technological innovation and favorable policies, China's imaging equipment has gradually broken technical barriers in the low-end field, and has continuously broken through into the blue ocean of the market
.
The industry believes that the domestic medical imaging equipment market space is huge.
In 2020, the scale of China's medical imaging market will be about 600 billion to 800 billion yuan.
In the future, there is still room for domestic alternatives to be tapped
.
In the face of the considerable market blue ocean, a number of enterprises including Mindray Medical, Neusoft Medical, and Wandong Medical have been actively deployed
.
Recently, news of United Imaging Medical's first launch meeting came.
In the next step, United Imaging Medical will submit for registration and is expected to be listed in 2022
.
According to the data, United Imaging Medical was established in March 2011.
It is an enterprise dedicated to providing high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions to global customers
.
The company is headquartered in Shanghai, and has established regional headquarters and R&D centers in the United States, Malaysia, the United Arab Emirates, Poland and other places, and has deployed production capacity in Shanghai, Changzhou, Wuhan, and Houston in the United States, and has established a global R&D, production and service network
.
Financial data shows that the company has been in a state of loss before the epidemic in 2020.
In 2020, medical institutions have increased demand for CT and mobile DR products, driving the company's related product revenue growth
.
From 2019 to 2021, United Imaging Medical achieved revenue of 2.
979 billion yuan, 5.
761 billion yuan and 7.
254 billion yuan respectively, the compound growth rate of revenue was 56.
03%, and the net profit attributable to the parent in the same period was -73.
5198 million yuan, 903 million yuan and 1.
417 billion yuan respectively.
yuan, showing a rapid growth trend
.
However, the proportion of R&D has shown a downward trend year by year
.
From 2019 to 2021, United Imaging Medical's R&D investment was 690 million yuan, 850 million yuan and 1.
048 billion yuan respectively, accounting for 23.
17%, 14.
76% and 14.
45% of its operating income, respectively
.
It is reported that although the proportion of the company's research and development has decreased year by year, it is still at a relatively high level among domestic enterprises in the industry
.
With high R&D investment, United Imaging Medical has a wealth of products.
By the end of 2021, United Imaging Medical has cumulatively launched magnetic resonance imaging systems (MR), X-ray computed tomography (CT), and X-ray imaging systems (XR) to the market.
, molecular imaging system (PET/CT, PET/MR), medical linear accelerator system (RT) and more than 80 products including life science instruments, etc.
, have a certain dominant position in the fields of computer equipment and magnetic resonance imaging
.
United Imaging Medical said that if the company’s future R&D investment is insufficient, or it is limited by uncertain factors such as R&D personnel and R&D conditions, it may lead to the failure to develop new products as planned, the industrialization of research projects, or the development of new products.
There is no competitive advantage in technology, performance, cost, etc.
, which in turn affects its competitive position and market share in the industry
.
It is worth mentioning that United Imaging Medical is favored by capital, and has completed 5 rounds of financing before the IPO.
The investors include CICC, CITIC Securities, CDB Securities and other securities institutions
.
Among them, in September 2017, it received 3.
333 billion yuan in Series A financing, setting a new record for a single private equity financing in China's medical imaging equipment industry, and its valuation has also risen
.
After the exercise of the over-allotment option, United Imaging Medical plans to issue 115 million shares, raise no less than 12.
48 billion yuan, and issue a valuation of more than 100 billion yuan
.
According to the industry, if United Imaging Medical is successfully listed, it may become the second company with a market value of 100 billion in the industry after Mindray Medical.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
